Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .
Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients.
The effects of pravastatin on plasma lipid levels , in vitro oxidizability of the non-HDL fraction , metabolic control , urinary albumin excretion , and four serum enzymes ( SGPT , SGOT , GT and CPK ) were studied in 20 insulin-dependent diabetic patients ( IDDM ) with incipient nephropathy . The patients were divided into two groups and the study was carried out by a crossover design . After 12 weeks pravastatin treatment ( 20 mg daily ) , plasma cholesterol , LDL-cholesterol and apolipoprotein B ( Apo B ) decreased by 22 , 19 and 15 % , respectively . The thiobarbituric acid reactive substances ( TBARS ) formation and the oxidation lagtime of the non-HDL fraction during the in vitro incubation with copper were not changed before and after treatment . The HbA1c and blood glucose levels , urinary albumin excretion , SGOT , SGPT and GT were not influenced by pravastatin treatment . CPK activity was elevated after 12 weeks of pravastatin treatment , and this elevation persisted even after the 12 weeks placebo period . So , pravastatin could be used as an effective drug for IDDM patients with incipient nephropathy , but close monitoring of the CPK activity is recommended
Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .